10:33 AM EDT, 03/11/2024 (MT Newswires) -- AbCellera (ABCL) said Monday it has entered into a collaboration with Biogen (BIIB) to discover ways to enable biologics to cross the blood-brain barrier and treat neurological diseases.

AbCellera will get an upfront payment and may receive milestone payments and potential royalties on future net sales. Financial details weren't provided.

AbCellera shares were rising past 3% in recent trading, while Biogen was up 1.2%.

Price: 4.92, Change: +0.15, Percent Change: +3.15